342631-41-8

Usage

Uses

Used in Pharmaceutical Industry:
Tenofovir Related Compound 1 is used as a reagent for the synthesis of amidate prodrugs of PMEA and PMPA, which are key components in the development of antiviral medications. These prodrugs have demonstrated potent antiviral activity and are used to treat various viral infections, including HIV/AIDS and Hepatitis B.
Used in Research and Development:
Tenofovir Related Compound 1 is also used as a reagent in the preparation of tenofovir alafenamide fumarate impurity. This application is crucial for the quality control and optimization of the manufacturing process, ensuring the safety and efficacy of the final drug product.

Upstream product

• 379270-35-6 ((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphoric acid monophenyl ester 
• 108-95-2 phenol 
• 147127-20-6 tenofovir 

Downstream Products

• 180587-75-1 (R)-diethyl (((1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate 
• 201341-05-1 tenofovir disoproxil 

Relevant academic research and scientific papers

Preparation method of high-purity tenofovir alafenamide impurity TAF-Y

The invention discloses a preparation method of a high-purity tenofovir alafenamide impurity TAF-Y. The preparation method comprises the following steps of performing chlorination on 9-[(R)-2-[[(phenoxyl phosphinyl)methoxyl]propyl]]adenine (TAF-M1), so as

A TAF nucleoside derivatives and intermediates thereof

The invention discloses a preparation method of a TAF (tenofovir alafenamide fumarate) nucleoside derivative and an intermediate of the TAF nucleoside derivative. The method comprises the steps that in a solvent of a compound II, in the presence of alkali, stirring is performed until the reaction is completed, and a required compound I is obtained. Compared with the prior art, the preparation method has the advantages that the raw materials are cheap and are easily obtained; the reaction conditions are mild; the side reactions are few; the yield is high; the environment pollution is little; the preparation method is applicable to industrial production; a new path is provided for the preparation of the TAF key intermediate. The formulas are shown in the specification.

A key intermediate for the preparation of fumaric acid for fuwei ira phenol amine (by machine translation)

The invention the invention belongs to the field of drug synthesis, relates to a pharmaceutical intermediates, in particular to a method for the preparation of a key intermediate in the fumaric acid for fuwei ira phenol amine. The present invention provid

Preparation method of TAF (Tumor Angiogenesis Factor) nucleoside derivative

The invention discloses a preparation method of a TAF (Tumor Angiogenesis Factor) nucleoside derivative. The method comprises the following steps: adding a compound II into alkali and a catalyst in a solvent, and stirring till the reaction is complete, thus obtaining a compound I. Compared with the prior art, raw materials used in the preparation method are readily available, reaction conditions are mild, little side effects are caused, the yield is high, the environmental pollution is low, and the preparation method is suitable for industrial production; a new way is provided for preparation of a fumarate tenofurol phenolamine key midbody.

Preparation method of amino phosphate ester derivatives and preparation method of intermediates and intermediates characterized in that at 0 DEG C -100 DEG C and in a solvent, the compound represented by the general formula (II) is subjected to an amino deprotection reaction in the presence of an alkaline reagent, an acidic reagent or a hydrogenolysis catalyst

The present invention relates to a process for the preparation of an amino phosphate ester derivative having antiviral activity as shown in the general formula (I) and a process for the preparation of intermediates and intermediates thereof, characterized in that at 0 DEG C -100 DEG C and in a solvent, the compound represented by the general formula (II) is subjected to an amino deprotection reaction in the presence of an alkaline reagent, an acidic reagent or a hydrogenolysis catalyst; the solvent used in the reaction is selected one or two from the group consisting of alcohol solvents, aromatic hydrocarbon solvents, ether solvents, halogenated alkane solvents, ester solvents, ketone solvents, lipid solvents, amide solvents, sulfoxide solvents and water; the acidic reagent is selected from organic acids or inorganic acids; the alkaline reagent is selected one or two from the group consisting of alkali metal hydroxides, alkaline earth metal hydroxides, alkali metal carbonates, alkaline earth metal carbonates and organic amines.

Method of preparing nucleoside analogs and intermediates thereof which has advantages of high reaction yield, high product purity, convenient post-treatment, and suitable for industrial mass production

The present invention relates to a method of preparing nucleoside analogs and intermediates thereof, which is the method of preparing the compound as shown by formula (I) and intermediates thereof. The disclosed method has advantages of high reaction yield, high product purity, convenient post-treatment, and suitable for industrial mass production, wherein the compound (III) is the key intermediate to produce the high purity compound (I), and the definitions of the substitution groups in the compound (III) are the same as those in the specification.

Tenofovir alafenamide fumarate impurity preparing method

The invention relates to a novel synthetic method of three tenofovir alafenamide fumarate impurities. The synthetic method has important significance in synthesis of high-quality tenofovir alafenamide fumarate. The invention mainly aims at studying synthe